Bryan Johnson reveals diagnosis of incurable autoimmune gastritis
Technology entrepreneur Bryan Johnson has revealed a diagnosis of autoimmune gastritis, an immune-mediated disorder affecting his stomach lining. He intends to explore experimental interventions to address the condition, which is currently considered incurable by medical standards.
Bryan Johnson, a 48-year-old technology entrepreneur and longevity advocate, has publicly disclosed a diagnosis of autoimmune gastritis (AIG), a chronic condition in which the immune system targets the stomach lining. Johnson, widely recognized for his high-cost health optimization project known as Blueprint, shared that he had been living with the undiagnosed condition for over 11 years.
Describing the process as his stomach eating itself
, Johnson detailed a decade-long medical mystery characterized by persistent iron deficiency. Despite following an extremely disciplined health regimen that monitors biomarkers with high precision, Johnson noted that standard medical assessments frequently failed to identify the underlying cause of his low ferritin levels, largely because his hemoglobin and hematocrit levels remained within normal ranges. Medical professionals often disregard low ferritin when anemia is not yet present, a diagnostic blind spot that Johnson believes delayed his identification of the condition for over 11 years. Johnson noted that the earliest clue, low ferritin, is the one standard medicine waves through, with low iron stores rarely investigated when anemia has not yet manifested.
Media additions
The investigation that led to his formal diagnosis in May involved a comprehensive clinical review. Following a clean colonoscopy, which ruled out colon cancer, his medical team conducted a bi-directional endoscopy and blood biomarker analysis. Results indicated elevated levels of anti-parietal-cell antibodies—which attack the cells responsible for producing stomach acid and intrinsic factor—and gastric biopsies ultimately confirmed early-stage atrophy of the stomach lining. Johnson stated that the findings showed atrophy in the acid-producing stomach lining, with no evidence of H. Pylori infection.
Understanding Autoimmune Gastritis
Autoimmune gastritis, sometimes called autoimmune atrophic gastritis, is an immune-mediated disorder where the body attacks parietal cells in the fundus and corpus of the stomach. This interference prevents the body from properly absorbing iron and vitamin B12, leading to potential complications such as anemia, nerve damage, and long-term neurological impairment. Health experts suggest that the prevalence of the condition may be higher than recorded figures, as the disease frequently hides in asymptomatic patients. Estimates of the condition's prevalence vary, with some figures suggesting it affects 2 to 5 percent of the population, while other data indicates it may affect between 0.5 and 4.5 percent of people.
Johnson’s medical history includes a diagnosis of hypothyroidism at age 21, for which he has taken hormone replacement therapy including levothyroxine and Armour Thyroid. Medical literature identifies a clinical link between autoimmune thyroid disease and AIG, a pairing sometimes referred to as thyrogastric syndrome. Johnson noted that his thyroid condition and the AIG, which drove his low iron, were linked in a cycle where low iron impairs the conversion of thyroid hormone, and an underactive thyroid impairs the body's use of iron.
Clinical Approach and Future Interventions
While AIG is currently considered incurable by standard medical practice, Johnson has sought to manage his nutritional deficits, receiving a 1,000 mg intravenous iron infusion to correct his ferritin levels. However, he has signaled an intention to challenge the current medical consensus that the condition can only be managed rather than resolved. His plan involves a multi-tiered strategy:
- Routine Monitoring: Regular tracking of biomarkers including ferritin, iron, B12, gastrin, and chromogranin A.
- Tissue Analysis: Repeated gastric biopsies to monitor the progression or potential reversal of stomach lining atrophy.
- Experimental Research: Active exploration of immune-pathway interventions, specifically targeting regulatory T cells, antigen-specific tolerance, and potentially engineered cell therapies.
Johnson has explicitly requested collaboration from specialists working on CAAR-T (chimeric autoantibody receptor T-cell) therapies or organ-specific autoimmunity. He maintains that his experience serves as a broader reminder that the absence of symptoms does not equate to the presence of health. He intends to publicly document his efforts to find a solution for the disease. As reported by the New York Post, Uniladtech, Livemint, and NewsX, the entrepreneur plans to remain transparent regarding his clinical findings and the efficacy of his experimental attempts to address the underlying autoimmune mechanism.
